Howard A. Burris

TL;DR: This abbreviated course of rituximab/chemotherapy, followed by maintenance ritUXimab, was active and well tolerated in these very elderly patients and merit further evaluation in this setting.

TL;DR: In a community-based phase II trial conducted in 39 elderly or poor performance status patients with advanced non--small cell lung cancer, weekly 36 mg/m(2) docetaxel produced a response rate of 20%, similar to those achieved with other active single agents.

TL;DR: The pharmacokinetic profile of rucaparib was further evaluated at the recommended phase 2 dose of 600 mg BID (n = 26) and the mean (coefficient of variation) steady‐state maximum concentration (Cmax) and area under the concentration‐time curve from time zero to 12 hours (AUC0‐12h) were 1940 ng/mL and 16 900 ng ⋅ h/mL, respectively.

TL;DR: Despite the use of QT‐prolonging antiemetics, treatment with romidepsin did not markedly prolong the QTc interval through 24 h, and increases in calculated QTC may have been exaggerated as a consequence of transient increases in heart rate.